Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 12Pancreatic Neoplasms 7Nasopharyngeal Carcinoma 5Cholangiocarcinoma 5Biliary Tract Neoplasms 4Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colonic Neoplasms 3Cirrhosis, Familial, with Pulmonary Hypertension 3Stomach Neoplasms 2Neoplasm Metastasis 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Neuroendocrine 2Urinary Bladder Neoplasms 1Rare Tumour 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Neoplasms, Second Primary 1Neoplasms 1Neoplasm, Residual 1Neoadjuvant Chemotherapy 1Muscle Neoplasms 1Locally Advanced Low Rectal Adenocarcinoma 1Liver Neoplasms 1Liver Metastases of Colorectal Cancer 1Keratosis, Actinic 1HER2-positive Gastric Cancer 1Gastroesophageal Junction Cancer 1

Interventions

Radiosurgery 1Panitumumab 1Leucovorin 1Irinotecan 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasms, Second Primary × Fluorouracil × Clear all
NCT04034173 2019-07-26

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Ludwig-Maximilians - University of Munich

Phase 2 Not yet recruiting
120 enrolled
Gastrointestinal

Colorectal Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡